MV BioTherapeutics SA (MV) is a Swiss Microbiome Biotherapeutics & Vaccines company, a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. MV discovered adenosine triphosphate (ATP) as a crucial signaling molecule in the intestinal microbiome leading to the apyrase (Apy) technology platform. The Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):